Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.

Channing J Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N Durham, Nilofer S Azad, Daniel A Laheru, Ilene Browner, Sushant K Kachhap, Kavya Boyapati, Thomas Odeny, Deborah K Armstrong, Christian F Meyer, Stephanie Gaillard, Julie R Brahmer

February 2023

Synopsis of Social media discussions

The overall tone reflects a positive outlook, emphasizing the trial's safety and promising improvements in quality of life, with mentions of leading researchers and institutions supporting its significance; phrases like 'important step' and 'advancing science' highlight both enthusiasm and recognition of its potential impact.

A
Agreement
 Moderate agreement

Most discussions recognize the trial's safety and potential benefits, reflecting a general positive sentiment towards the research.

I
Interest
 High level of interest

Posts express high interest by highlighting the significance of the trial's progress and potential implications for cancer treatment.

E
Engagement
 Moderate level of engagement

Conversations show moderate engagement through mentions of specific researchers, institutions, and implications of the trial, but lack deep critical analysis.

I
Impact
 Moderate level of impact

The collective tone suggests the trial may influence future research and clinical practices, though it remains in early stages.

Social Mentions

YouTube

3 Videos

Twitter

22 Posts

Blogs

3 Articles

News

74 Articles

Metrics

Video Views

12,174

Total Likes

464

Extended Reach

261,162

Social Features

102

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Intravenous Mistletoe Extract in Advanced Cancer: Safety and Potential Benefits

Intravenous Mistletoe Extract in Advanced Cancer: Safety and Potential Benefits

This phase I clinical trial tests the safety and dosage of intravenous mistletoe extract in patients with advanced cancers, showing manageable side effects and some disease stabilization, highlighting the need for further research.

off the city

January 26, 2025

8,769 views

Intravenous Mistletoe Shows Promise in Advanced Cancer Treatment

Intravenous Mistletoe Shows Promise in Advanced Cancer Treatment

At GWCIM, we have recommended IV mistletoe for advanced cancer based on European studies. The recent US phase I trial suggests safety and potential disease stabilization, with some patients experiencing longer stable periods and improved quality of life.

Dr. Misha Kogan

February 15, 2023

2,874 views

Mistletoe Therapy in Oncology: Safety and Potential Benefits

Mistletoe Therapy in Oncology: Safety and Potential Benefits

Mistletoe has long been associated with the holiday season but few people know its rich history and powerful potential in integrative oncology. This episode explores the science, mechanisms, and innovative applications of mistletoe therapy in cancer treatment, highlighting its immune-modulating and anti-inflammatory effects

Prescribed

December 17, 2024

531 views

  • Steve K
    @SteveKe61657969 (Twitter)

    https://t.co/t6CYyrHggI
    view full post

    October 9, 2024

  • Facts Are Good
    @Facts_R_Good (Twitter)

    @MaryCol81396498 @KateShemirani What makes you think you can’t? https://t.co/qifNkKIdro
    view full post

    November 6, 2023

  • Dr. Paul Theriault BSc, ND, FNMI, CBC
    @DrPaulND (Twitter)

    A new phase 1 clinical trial of Mistletoe in Cancer was safe, and showed considerable improvement in quality of life. #Naturopathic https://t.co/fdSZf4UGqQ
    view full post

    March 16, 2023

    1

  • NP AGARWAL世界一フォローを目指しますAiming best in world.
    @np_grwl (Twitter)

    RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X
    view full post

    March 3, 2023

    3

  • Ana Maria Lopez, MD, MPH, MACP
    @anamarialopezmd (Twitter)

    Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer https://t.co/NH8ZvFN3x9
    view full post

    February 24, 2023

  • サイエンスあれこれ
    @sarekore (Twitter)

    では数十年にわたり、がん治療単独または化学療法や放射線療法と組み合わせた補完医療として使用されてきましたが、臨床試験では評価されていません。ME は現在、FDAに承認されていませんが、ホメオパシー薬局方に掲載されており、統合医療クリニックで提供されています。 https://t.co/QNRNWHI9kj
    view full post

    February 24, 2023

  • Stacey
    @StaceG03 (Twitter)

    RT @write4wellness: First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Pa…
    view full post

    February 23, 2023

    2

  • Society for Integrative Oncology
    @Integrativeonc (Twitter)

    RT @write4wellness: First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Pa…
    view full post

    February 23, 2023

    2

  • Jodi MacLeod
    @write4wellness (Twitter)

    RT @Integrativeonc: The team at @hopkinskimmel, led by SIO Vice President of Advancement Channing Paller @Cpaller, completed the first phas…
    view full post

    February 23, 2023

    1

  • Jodi MacLeod
    @write4wellness (Twitter)

    First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Paller, MD, and team and @believebig1 for advancing #integrativeoncology science. @Integrativeonc https://t.co/uKyi6soMnY https://t.co/S2p0zvCo6V
    view full post

    February 23, 2023

    6

    2

  • Society for Integrative Oncology
    @Integrativeonc (Twitter)

    The team at @hopkinskimmel, led by SIO Vice President of Advancement Channing Paller @Cpaller, completed the first phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Check out the article here ➡️https://t.co/dybq8LQE2i #integrativeonc #MistletoeTherapy
    view full post

    February 23, 2023

    2

    1

  • haber
    @ilimlevebilimle (Twitter)

    RT @ilyassahinMD: 1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıc…
    view full post

    February 22, 2023

    2

  • Wafik S. El-Deiry, MD, PhD, FACP
    @weldeiry (Twitter)

    Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer https://t.co/mfAeqD4Lfp
    view full post

    February 22, 2023

  • Steve Dudley, M.D.
    @bsdudleymd (Twitter)

    Important step toward making this agent available to more USA patients. #IntegrativeOncology "Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer" . https://t.co/IBbq59krNu
    view full post

    February 22, 2023

  • Ahmet
    @AhmetYl83272735 (Twitter)

    RT @ilyassahinMD: 1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıc…
    view full post

    February 22, 2023

    2

  • ilyas sahin, MD
    @ilyassahinMD (Twitter)

    1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıca yaşam kalitesine ve hastalık faydasına da baktı. https://t.co/qJ9fI9AYK2
    view full post

    February 22, 2023

    22

    2

  • Manu Gupta
    @guptam108 (Twitter)

    RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X
    view full post

    February 22, 2023

    3

  • BELIEVE BIG
    @believebig1 (Twitter)

    RT @CRC_AACR: Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/09QsmZdXNp @hopkinskimmel…
    view full post

    February 22, 2023

    1

  • Medical Xpress
    @physorg_health (Twitter)

    RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X
    view full post

    February 22, 2023

    3

  • Medical Xpress
    @medical_xpress (Twitter)

    Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X
    view full post

    February 22, 2023

    4

    3

  • Cancer Research Communications
    @CRC_AACR (Twitter)

    Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/09QsmZdXNp @hopkinskimmel #openaccess https://t.co/AhUdL7sNbk
    view full post

    February 20, 2023

    3

    1

  • Cancer Research Communications
    @CRC_AACR (Twitter)

    Just published— Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/8fk7erX1Ig @hopkinskimmel #openaccess https://t.co/GrQ49gfy32
    view full post

    February 9, 2023

    2

Abstract Synopsis

  • This study was a phase I clinical trial testing the safety and appropriate dosage of intravenous mistletoe extract (Helixor M) in patients with advanced, hard-to-treat cancers, showing it has manageable side effects and some potential to stabilize disease and improve quality of life.
  • The maximum tolerated dose was 600 mg, with common side effects like fatigue and nausea, but no objective tumor shrinkage was observed; however, some patients experienced disease stabilization and slower increases in tumor markers.
  • The results suggest that intravenous mistletoe might be safe and could offer benefits in disease control and quality of life, indicating that further research with larger, more definitive trials is needed to confirm its effectiveness.]